Regd.Off: 4th FIr, Plot No. 94, Sagar Society, Road No.2, Banjara Hills, Hyderabad-500034 TS Works: 9-109/9, Plot No.112, Road No. 14, Gayatri Nagar, Bouduppal, Hyderabad - 500 039 Ph: (+91)-40-48536100 Url: www.decipherlabs.in Mail: decipherlabsltd@gmail.com DLNo.TG/15/04/2016-14766/14767 CINNo.L24230TG1986PLC006781 GST:36AAACC8372L1ZB

30/04/2020

To,
The General Manager
Department of Corporate Services – CRD
BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai 400 001.

Sir,

Ref: Qtrly Compliance - Reconciliation of Share Capital Audit Report - Reg 55A

Dear Sir,

Please find enclosed hereto the Reconciliation of Share Capital Audit Report in the prescribed format, as certified by the Practicing Company Secretary, for the quarter ended 31st March, 2020.

We kindly request you to take the same on record.

Thanking You,
Yours Sincerely,
For **DECIPHER LABS LIMITED**

Kumar Raghavan
COMPANY SECRETARY &
COMPLIANCE OFFICER

ABS LIFE Hyderabad D



The Board of Directors **DECIPHER LABS LIMITED**(Formerly known as Combat Drugs Limited)

Plot No. 94, 4th Floor, Road No. 2,

Sagar Society, Banjara Hills,

Hyderabad ,Telangana ,500034.

Reconciliation of Share Capital Audit Report

Dear Sir

We have examined the Register of Members and other records / documents maintained by M/s **DECIPHER LABS LIMITED** (Formerly known as Combat Drugs Limited) and according to the explanations given to us and based on such verification as necessary, we are enclosing hereto a Reconciliation of Share Capital Audit Report in accordance with the Circular D&CC/FITTC/CIR-16/2002 dated December 31, 2002 and CIR/MRD/DP/30/2010 dated 06th September 2010 issued by the Securities and Exchange Board of India, for the guarter ended **31st March 2020**.

Date: 29-04-2020 Place: Hyderabad



RECONCILIATION OF SHARE CAPITAL AUDIT REPORT

(as per regulation 55A of the SEBI (Depositories and participants) Regulations, 1996)

1.	For the Quarter Ended			31 st March 202	20
2.	ISIN:			INE643N01012	2
3.	Face Value :			Rs.10/-	
3.	race value.			KS.10/-	
4.	Name of the Company		R LABS LIMIT nown as Combat		
5.	Registered Office Address		4th Floor, Road abad ,Telangana		ociety, Banjara
6.	Correspondence Address	-	4th Floor, Road		ociety, Banjara
		111115 ,117 401	uouu ,1 oluligalla	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
7.	Telephone & Fax Nos.	(040) 48536	100		
8.	Email Address	cs@combate	drugs.in		
9.	Name of the Stock Excha the company's securities are				
					0/ C.T 1
				Number of shares	% of Total Issued Capital
10.	Issued Capital			1,01,00,000	100.00%
11.	Listed Capital (Exchange-wise) : in BSE			1,01,00,000	100.00%
	(as per company records)				
12.	Held in dematerialized form in NSDL			31,86,881	31.55%
13.	Held in dematerialized form in CDSL			61,26,256	60.66%
14. Physical 7,86,863			7,86,863	7.79%	
15.	Total No. of shares (12+13+		1,01,00,000	100.00%	
16.	Reasons for difference if any, between [(10&11), (10& 15), (11&15):			NIL	



17. Certifying the details of changes in share capital during the quarter under consideration as per Table below:

Particulars*	No. of shares	Applie d / Not Applie d for listing	Listed on Stock Exchange s	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Approval. Pending for SE (Specify Names)
Issue of Equity Shares to Mr.Pavan Mantripragada & Mrs.Janaki Yenamandra,No n-Promoters of the Company, at a price of Rs.40/- (including premium of Rs.30/-)	21,00,000 Equity Shares of Rs:10/- each	Listed	Yes – Bombay Stock Exchange	Yes (The Company received Approval vide Letter No.CDSL /OPS/AT/ 2019-20/18760 Dated 12-03-2020	Yes (The Company received Approval vide Letter No.II/CA/COM/106 03/2020 Dated 06-03-2020	The Company received Listing Approval vide Letter No.DCS/PREF/PB/F IP/544/2019-20. Dated 28-02-2020 & Trading Approval vide Letter No.DCS/PREF/TP/P B/10279/2019-20. Dated 11-03-2020 from BSE.

^{*} Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Cap. Reduction, forfeiture, Any other (to specify)

18.	Register of Members is updated (Yes/No)	YES	
	If not, update up to which date		
19.	Reference of previous quarter with regard to excess dematerialized shares, if any.	N.A	
20.	Has the company resolved the matter mentioned in point No.19 above in the current quarter? If not, reason why?	-N.A	

21. Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:

Total No. of demat requests	No. of requests	No. of shares	Reasons for delay
Confirmed after 21 Days	-NIL-	-NIL-	-NIL-
Pending for more than 21 days	-NIL-	-NIL-	-NIL-

S.S. MARTHI & CO.
COMPANY SECRETARIES

S.S. MARTHI
COMPANY SECRETARY
F.C.S-1989 CP-1937

22.	Name, Telephone & Fax No. of		
	the Compliance Officer of the	Company Secretary and Compliance Officer.	
	Co.	Telefax 040-48536100.	
		Email Id: <u>cs@combatdrugs.in</u>	
23.	Name, Address, Tel. & Fax No.,	S.S.Marthi, Marthi & Co.,	
	Regn. No. of certifying CS.	Flat No.201, Moghal's Emami Mansion,	
		Chintalbasti Road, Khairatabad, Hyderabad – 500	
		004. Phones: (040) 23374169, Fax: (040)	
		23374169)	
24.	Appointment of common	VENTURE CAPITAL AND CORPORATE	
	agency for share registry work	INVESTMENTS PVT LTD,	
		#12-10-167, Bharath Nagar, Hyderabad-500 018.	
		Ph No-040-23818475, 23818476, 23818457	
25.	Any other detail that the CA/CS may like to provide. (e.g. BIFR company, delisting from SE,	Combat Drugs Limited to Decipher Labs Limited	
	Name change, etc.)	w.e.f25- 01-2020.	

